Westpac Banking Corp Has $2.11 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Westpac Banking Corp lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 292.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,311 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 shares during the period. Westpac Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $2,112,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. iA Global Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares during the period. Perpetual Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $2,004,000. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 24.2% during the 3rd quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock valued at $54,248,000 after acquiring an additional 23,168 shares during the period. Finally, Linden Advisors LP acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $6,550,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 7,740 shares of company stock valued at $2,420,214. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $292.58 on Thursday. The firm has a market capitalization of $39.06 billion, a PE ratio of 79.94 and a beta of 0.29. The firm has a fifty day simple moving average of $308.26 and a two-hundred day simple moving average of $350.71. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $283.10 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business posted ($0.44) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% on a year-over-year basis. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ALNY shares. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research report on Friday, May 1st. Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. HC Wainwright restated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.